GMP Audit for ATMPs: Advanced Therapy Medicinal Products

What ATMP GMP Audits Cover

Advanced therapy medicinal products, or ATMPs, include gene therapy, somatic cell therapy, and tissue engineered products. They present GMP challenges that differ from conventional pharmaceuticals. Starting materials may be patient derived. Batch sizes may be small. Product may be patient specific. The time from collection to administration may be short. These factors shape how GMP is applied and how audits are conducted.

An ATMP GMP audit assesses whether the manufacturing operation meets the GMP requirements applicable to these products, with attention to the specific risks they present. That includes donor eligibility and testing, traceability from donor to recipient, aseptic processing, viral vector safety where applicable, and the controls that prevent mix ups and cross contamination in a multi patient environment.

The Regulatory Context for ATMP GMP

EU Regulation 1394/2007 and GMP for ATMPs

The EU regulates ATMPs under Regulation 1394/2007, which sits alongside the Clinical Trials Regulation and the GMP Directive. EudraLex Volume 4 applies, and the EMA has published guidelines on GMP for ATMPs that address specific issues such as donor eligibility, traceability, and the use of starting materials.

FDA 21 CFR Part 1271 and cGMP

The FDA regulates human cells, tissues, and cellular and tissue based products under 21 CFR Part 1271, which includes donor eligibility requirements. cGMP requirements under 21 CFR Parts 210 and 211 apply, and the FDA has published guidance on GMP for cell and gene therapy products.

ICH Q5A and Viral Safety

For gene therapy products, ICH Q5A provides guidance on viral safety evaluation of biotechnology products derived from cell lines.

Health Canada and ATMP Oversight

Health Canada regulates cell and gene therapies under the Food and Drug Regulations and has published guidance on their manufacture and testing.

MHRA and ATMP Inspections

The MHRA inspects ATMP manufacturing sites and has published guidance on expectations for these products, including traceability and donor testing.

What ATMP Audits Focus On

Donor Eligibility and Testing

Donor eligibility determination and testing for relevant communicable disease agents are core requirements. The audit should check the process, the documentation, and the review by a responsible person.

Traceability

Traceability from donor to recipient and back is essential. The audit should check that the chain is complete, documented, and verifiable.

Aseptic Processing

Many ATMPs cannot be terminally sterilized, so aseptic processing is critical. The audit should check facility design, environmental monitoring, personnel practices, and media fill design.

Starting Materials

Starting materials may include cells, tissues, vectors, and reagents. The audit should check qualification, testing, and control.

Viral Vector Safety

For gene therapies, the audit should check viral vector production, testing, and clearance where applicable.

Chain of Identity and Chain of Custody

For patient specific products, the chain of identity and chain of custody must be robust. The audit should check the systems and documentation that support them.

Cross Contamination and Mix Ups

Multi patient processing creates risks of cross contamination and mix ups. The audit should check segregation, cleaning, and identification controls.

Release Testing

Release testing for ATMPs may be limited by product quantity and stability. The audit should check the testing strategy and the justification for any reduced testing.

Common Findings in ATMP Audits

Incomplete Donor Eligibility Documentation

Traceability Gaps in the Chain of Identity

Aseptic Processing Weaknesses

Starting Material Qualification Gaps

Viral Vector Testing Gaps

Cross Contamination Controls That Are Not Fully Implemented

Introducing GxP Cellators for ATMP Audits

GxP Cellators provides GMP audits for ATMPs across the manufacturing, testing, storage, and distribution chain. Our audits cover donor eligibility, traceability, aseptic processing, starting materials, viral vector safety, chain of identity and custody, cross contamination controls, and release testing.

We work across FDA, EMA, Health Canada, MHRA, WHO, and PIC/S frameworks, and we adapt the audit scope to the product type and the regulatory requirements that apply. Our auditors bring regulatory inspection and industry quality experience, and we deliver clear, prioritized reports with practical remediation guidance.

We also provide pre approval inspection readiness audits and mock regulatory inspections for ATMP facilities preparing for inspection.

Prepare for ATMP Compliance

Visit https://www.gxpcellators.com/gmp-auditing/ for service details. Email or use https://www.gxpcellators.com/contact/ to discuss your ATMP audit.

Frequently Asked Questions About ATMP GMP Audits

What makes ATMP GMP different from conventional pharmaceuticals?

ATMPs often use patient derived starting materials, have small batch sizes, and may be patient specific. Traceability, aseptic processing, and chain of identity are more critical.

What is donor eligibility?

Donor eligibility is the determination that a donor meets the requirements for communicable disease testing and risk assessment. It is a core requirement for many ATMPs.

What is chain of identity?

Chain of identity is the documented link between a patient, their cells or tissues, and the final product. It prevents mix ups and supports traceability.